|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
FibroGen, Inc. Reports Data from Phase 2 Study of FG-4592 Hemoglobin Correction and Maintenance in End-Stage Renal Patients
11/5/2012 9:58:21 AM
SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced that data from an ongoing Phase 2 study of FG-4592, an orally delivered, small molecule treatment for anemia, were presented on 2 November 2012, at the American Society of Nephrology (ASN) Kidney Week 2012 in San Diego, California. The study was designed to compare FG-4592 , an investigational hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), with an active comparator (epoetin a) in patients with end-stage renal disease (ESRD) receiving hemodialysis, whose hemoglobin (Hb) levels were previously maintained with intravenous (IV) epoetin a and IV iron supplementation.
|
|
|
|
|
|
|
|
|
|
|